237 related articles for article (PubMed ID: 18270864)
1. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.
Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in cryoglobulinemic peripheral neuropathy.
Cavallo R; Roccatello D; Menegatti E; Naretto C; Napoli F; Baldovino S
J Neurol; 2009 Jul; 256(7):1076-82. PubMed ID: 19263187
[TBL] [Abstract][Full Text] [Related]
4. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
5. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G
Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225
[TBL] [Abstract][Full Text] [Related]
7. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
Ahmed MS; Wong CF
J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269
[TBL] [Abstract][Full Text] [Related]
8. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia.
Korte MR; van Heerde MJ; de Man RA; Betjes MH
Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients.
Basse G; Ribes D; Kamar N; Mehrenberger M; Esposito L; Guitard J; Lavayssière L; Oksman F; Durand D; Rostaing L
Transplantation; 2005 Dec; 80(11):1560-4. PubMed ID: 16371926
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose rituximab for mixed cryoglobulinemia.
Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M
Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.
Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F
Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023
[TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S
Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196
[TBL] [Abstract][Full Text] [Related]
15. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.
Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M
Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494
[TBL] [Abstract][Full Text] [Related]
16. Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study.
Roccatello D; Sciascia S; Baldovino S; Rossi D; Alpa M; Naretto C; Di Simone D; Menegatti E
Am J Nephrol; 2016; 43(4):251-60. PubMed ID: 27161362
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in mixed cryoglobulinemia: increased experience and perspectives.
De Vita S; Quartuccio L; Fabris M
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S122-8. PubMed ID: 17936213
[TBL] [Abstract][Full Text] [Related]
18. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.
Agnello V
Springer Semin Immunopathol; 1997; 19(1):111-29. PubMed ID: 9266635
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease.
Fabrizi F; Plaisier E; Saadoun D; Martin P; Messa P; Cacoub P
Am J Kidney Dis; 2013 Apr; 61(4):623-37. PubMed ID: 23102733
[TBL] [Abstract][Full Text] [Related]
20. [Current therapeutic strategies for HCV-associated cryoglobulinemia].
Iannuzzella F; Garini G
Reumatismo; 2008; 60(3):163-73. PubMed ID: 18854876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
